Skip to main content
. Author manuscript; available in PMC: 2014 Jun 5.
Published in final edited form as: Cell. 2013 Dec 5;155(6):1309–1322. doi: 10.1016/j.cell.2013.11.012

Figure 4. Variable expression of AR target genes in LREX’, in vivo, and after glucocorticoid treatment, in vitro.

Figure 4

A. Normalized expression array signal (Illumina HT-12) of a suite of 74 AR target genes in control (n=10), 4 day (n=8), and LREX’ (n=8, right) xenograft tumors. Genes are ranked by degree of restoration of expression in resistant tissue ((Res-4 day) / (Control-4 day)). All resistant tissues were continued on anti-androgen treatment through time of harvest. B. Fractional restoration values of each of the 74 AR targets in LREX’ xenografts (n=8) or resistant tissues from the validation cohort (n=12, see also Figure S3). C. GR mRNA in resistant tissues used in B. D. Expression of AR target genes in the LREX’ cell line in steroid depleted media after 8 hours of treatment with the indicated agonists, in vitro. Enzalutamide = 10 micromolar, V = Vehicle. +/− s.e.m. See also Figures S3, S4.